These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28644036)

  • 21. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Fails To Identify Nontuberculous Mycobacteria from Primary Cultures of Respiratory Samples.
    van Eck K; Faro D; Wattenberg M; de Jong A; Kuipers S; van Ingen J
    J Clin Microbiol; 2016 Jul; 54(7):1915-1917. PubMed ID: 27147723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.
    Jeon K; Kwon OJ; Lee NY; Kim BJ; Kook YH; Lee SH; Park YK; Kim CK; Koh WJ
    Am J Respir Crit Care Med; 2009 Nov; 180(9):896-902. PubMed ID: 19661243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.
    Koh WJ; Jeon K; Lee NY; Kim BJ; Kook YH; Lee SH; Park YK; Kim CK; Shin SJ; Huitt GA; Daley CL; Kwon OJ
    Am J Respir Crit Care Med; 2011 Feb; 183(3):405-10. PubMed ID: 20833823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.
    Plongla R; Preece CL; Perry JD; Gilligan PH
    J Clin Microbiol; 2017 May; 55(5):1469-1477. PubMed ID: 28228494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.
    Dalovisio JR; Pankey GA; Wallace RJ; Jones DB
    Rev Infect Dis; 1981; 3(5):1068-74. PubMed ID: 7339806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.
    Singh AK; Thakare R; Karaulia P; Das S; Soni I; Pandey M; Pandey AK; Chopra S; Dasgupta A
    J Antimicrob Chemother; 2017 Nov; 72(11):3117-3121. PubMed ID: 28961864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary disease due to Mycobacterium massiliense.
    Mitra S; Tapadar SR; Banerjee D; Bhattacharjee S; Dey S; Kundu S
    Indian J Chest Dis Allied Sci; 2012; 54(1):53-7. PubMed ID: 22779125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.
    Huang YC; Liu MF; Shen GH; Lin CF; Kao CC; Liu PY; Shi ZY
    J Microbiol Immunol Infect; 2010 Oct; 43(5):401-6. PubMed ID: 21075707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.
    Park J; Cho J; Lee CH; Han SK; Yim JJ
    Clin Infect Dis; 2017 Feb; 64(3):301-308. PubMed ID: 28011609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nontuberculous mycobacteria in respiratory infections: advances in diagnosis and identification.
    Somoskovi A; Salfinger M
    Clin Lab Med; 2014 Jun; 34(2):271-95. PubMed ID: 24856528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Distribution and drug resistance of nontuberculous
    Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
    [No Abstract]   [Full Text] [Related]  

  • 33. Medications and monitoring in nontuberculous mycobacteria infections.
    Egelund EF; Fennelly KP; Peloquin CA
    Clin Chest Med; 2015 Mar; 36(1):55-66. PubMed ID: 25676519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of a new culture medium in biochemical tests for the mycobacterial classification.
    Mederos LM; Gutierrez AM; Valdivia JA
    Mem Inst Oswaldo Cruz; 1992; 87(3):441. PubMed ID: 1343654
    [No Abstract]   [Full Text] [Related]  

  • 35. Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria.
    Fowler J; Mahlen SD
    Arch Pathol Lab Med; 2014 Aug; 138(8):1106-9. PubMed ID: 25076301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics.
    Nie W; Duan H; Huang H; Lu Y; Bi D; Chu N
    Int J Infect Dis; 2014 Aug; 25():170-4. PubMed ID: 24932856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ofloxacin in the treatment of pulmonary changes caused by Mycobacterium avium and Mycobacterium xenopii].
    Zwoliński J; Gałazka J
    Pneumonol Alergol Pol; 1992; 60(5-6):70-3. PubMed ID: 1290992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nontuberculous mycobacterial species and
    Mertaniasih NM; Kusumaningrum D; Koendhori EB; ; Kusmiati T; Dewi DN
    Int J Mycobacteriol; 2017; 6(1):9-13. PubMed ID: 28317798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan.
    Huang CW; Chen JH; Hu ST; Huang WC; Lee YC; Huang CC; Shen GH
    Int J Antimicrob Agents; 2013 Mar; 41(3):218-23. PubMed ID: 23312605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights in the treatment of nontuberculous mycobacterial pulmonary disease.
    Ruth MM; van Ingen J
    Future Microbiol; 2017 Oct; 12():1109-1112. PubMed ID: 28972416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.